Hypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Trial - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Blood Année : 2020

Hypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Trial

(1) , (2) , (3) , (4) , (4, 5) , , (6) , (7) , (8, 9) , (10, 11) , (12) , (13) , (14) , (4)
1
2
3
4
5
6
7
8
9
10
11
12
13
14

Résumé

Hypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Trial

Dates et versions

hal-03605964 , version 1 (11-03-2022)

Identifiants

Citer

Louise Bouard, Catherine Thieblemont, Krimo Bouabdallah, Thomas Gastinne, Anne Moreau, et al.. Hypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Trial. Blood, 2020, 136 (1), pp.42. ⟨10.1182/blood-2020-139990⟩. ⟨hal-03605964⟩
20 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More